Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Overcoming T cell exhaustion to improve CAR-T Therapy for Translocation Renal Carcinoma.

FY 2024-25

Summary
Translocation renal cell carcinoma (tRCC) represents the most common kidney cancer in pediatric patients, lacking effective therapy for advanced tRCC. These tumours overexpress the tumour-associated antigen GPNMB on the cell surface, making them an attractive target for CAR-T therapy. While attractive, resistance to CAR-T through induction of exhaustion (Tex) is a well-known challenge for most solid tumours. Interestingly, prior to becoming exhausted, CAR-Ts can take on a progenitor tissue resident-like state (Tpex), which has been demonstrated to be critical for antitumor therapeutic success. However, the mechanisms to promote this state are not understood in tRCC. We propose to establish an in vivo CRISPR screening approach to investigate the genes that maintain CAR-T cells in a Tpex state. Notably, we have already generated a GPNMB targeting CAR-T that displays efficacy against tRCC patient-derived cell lines and xenografts. We will perform in vivo CRISPR screening by using a gRNA library targeting the transcription factors (targeting ~1, 500 genes), building on previous studies that have identified transcription factors that can either support or antagonize the Tpex. Then, we will perform in vivo validation of the top ‘hit’ by creating knockout to GPNMB CAR-T to assess their tumour growth inhibition, check inhibitory molecules and gene expression of Tpex in the tumour microenvironment by single-cell RNA sequencing. Our findings will push the boundaries of understanding the gene regulation of Tpex in the presence of cancer cells. The hit transcription factor inducing Tpex from tRCC will be exploited to engineer more persistent next-generation GPNMB CAR-T cells to cure tRCC patients or patients suffering from other GPNMB-expressing tumours.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529812
Name
Choi Siwon
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Overcoming T cell exhaustion to improve CAR-T Therapy for Translocation Renal Carcinoma.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Car-T Therapy; Crispr Screening; Functional Genomics; Gpnmb; Humanized Mice; Single Cell Rna Seqeuncing; T Cell Exhaustion; Tcf1+ Progenitor Exhausted T Cell; Translocation Renal Cell Carcinoma; Tumor Microenvironment
Abstract
Translocation renal cell carcinoma (tRCC) represents the most common kidney cancer in pediatric patients, lacking effective therapy for advanced tRCC. These tumours overexpress the tumour-associated antigen GPNMB on the cell surface, making them an attractive target for CAR-T therapy. While attractive, resistance to CAR-T through induction of exhaustion (Tex) is a well-known challenge for most solid tumours. Interestingly, prior to becoming exhausted, CAR-Ts can take on a progenitor tissue resident-like state (Tpex), which has been demonstrated to be critical for antitumor therapeutic success. However, the mechanisms to promote this state are not understood in tRCC. We propose to establish an in vivo CRISPR screening approach to investigate the genes that maintain CAR-T cells in a Tpex state. Notably, we have already generated a GPNMB targeting CAR-T that displays efficacy against tRCC patient-derived cell lines and xenografts. We will perform in vivo CRISPR screening by using a gRNA library targeting the transcription factors (targeting ~1, 500 genes), building on previous studies that have identified transcription factors that can either support or antagonize the Tpex. Then, we will perform in vivo validation of the top ‘hit’ by creating knockout to GPNMB CAR-T to assess their tumour growth inhibition, check inhibitory molecules and gene expression of Tpex in the tumour microenvironment by single-cell RNA sequencing. Our findings will push the boundaries of understanding the gene regulation of Tpex in the presence of cancer cells. The hit transcription factor inducing Tpex from tRCC will be exploited to engineer more persistent next-generation GPNMB CAR-T cells to cure tRCC patients or patients suffering from other GPNMB-expressing tumours.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Choi, Siwon
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~